Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1594-1599

  Khatib, Riad ^a   Jose, Jinson ^a   Musta, Adina ^a   Sharma, Mamta ^a   Fakih, Mohamad G ^a   Johnson, Leonard B ^a   Riederer, Kathleen ^a   Shemes, Stephen ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

hVISA; MRSA; Outcome; VISA

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EPSILOMETER TEST; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PHENOTYPE; SCREENING; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 79958849079     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr169     Document Type: Article

References (32)

1. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and the outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
2. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
3. Wang G, Hindler JF, Ward KE et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-6.
4. Howden BP, Ward PB, Robson J et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
5. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment ofmethicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
6. Soriano A, Marco F, Martinez AJ et al. Influence of vancomycin minimal inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
7. Moise PA, Sakoulas A, Forrest A et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51: 2582-6.
8. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). Int Med J 2005; 35: S136-40.
9. Howden BP, Davies JK, Johnson PDR et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
10. Fridkin SK. Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108-15.
11. Tenover F, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
12. Voss A, Mouton JW, van Elzakker EP et al. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 2007; 6: 9-13.
13. Swenson JM, Anderson KF, Lonsway DR et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycinintermediate Staphylococcus aureus. J Clin Microbiol 2009; 47: 2013-7.
14. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
15. Hageman JC, Liedtke LA, Sunenshine RH et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43: e42-5.
16. Charles PGP, Ward PB, Johnson PDR et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
17. Falagas ME, Makris GC, Dimopoulos G et al. Heteroresistance: a concern of increasing clinical significance? Clin Microbiol Infect 2008; 14: 101-4.
18. Leonard SN, Rossi KL, Newton KL et al. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009; 63: 489-92.
19. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
20. Rybak MJ, Leonard SN, Rossi KL et al. Characterization of vancomycin heteroresistant Staphylococcus aureus (hVISA) from the Detroit Metropolitan area over a 22-year period (1986-2007). J Clin Microbiol 2008; 46: 2950-4.
21. Yusof A, Engelhardt A, Karlsson A et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol 2008; 46: 3042-7.
22. Delgado A, Riordan JT, Lamichhane-Khadka R et al. Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus isolate from medical center in Las Cruces, New Mexico. J Clin Microbiol 2007; 45: 1325-9.
23. Nunez AP, Schuenck RP, Reis Bastos CC et al. Heterogeneous resistance to vancomycin and teicoplanin among Staphylococcus spp. isolated from bacteremia. Braz J Infect Dis 2007; 11: 345-50.
24. Marchese A, Balistreri G, Tonoli E et al. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866-9.
25. Khatib R, Riederer K, Saeed S et al. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis 2005; 41: 594-8.
26. Khatib R, Johnson LB, Sharma M et al. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009; 41: 4-9.
27. Zhang K, McClure JA, Elsayed S et al. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005; 43: 5026-33.
28. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
29. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
30. Garnier F, Chainier D, Walsh T et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006; 57: 146-9.
31. Sancak B, Ercis S, Menemenlioglu D et al. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish hospital. J Antimicrob Chemother 2005; 56: 519-23.
32. Hussain F, Boyle-Vavra S, Shete PB et al. Evidence for continuum of decreased vancomycin susceptibility in unselected Staphylococcus clinical isolates. J Infect Dis 2002; 186: 661-7.